• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@İSÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed | DergiPark
  • WoS İndeksli Yayınlar Koleksiyonu
  • View Item
  •   DSpace@İSÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed | DergiPark
  • WoS İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Panvigilance: integrating biomarkers in clinical trials for systems pharmacovigilance

Thumbnail

View/Open

Tam Metin / Full Text (126.9Kb)

Date

2019

Author

Sardas, Semra
Kendirci, Asligul

Metadata

Show full item record

Citation

Sardas, S., & Kendirci, A. (2019). Panvigilance: Integrating Biomarkers in Clinical Trials for Systems Pharmacovigilance. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 23(3), 134–137. https://doi.org/10.1089/omi.2019.0020

Abstract

Drug safety and pharmacovigilance are rapidly changing with biomarkers and new technologies such as artificial intelligence. However, we need new ideas and application contexts for integration of biomarkers and emerging technologies in modern pharmacovigilance. A new concept, panvigilance, has been recently introduced for proactive "stress testing" of new drug candidates in panels of patients or healthy volunteers identified by biomarkers, and who are situated in population edges in terms of pharmacokinetic (PK) and/or molecular target interindividual variability. Panvigilance aims to provide upper and lower bound estimates for drug performance under conditions that mimic population edges. Subsequently, it becomes easier to extrapolate pharmacovigilance signals with regard to individuals who reside in between the population edges. In this expert review, we explain that the prefix "pan," meaning everything or all, refers to the three-pronged panvigilance goals to (1) decipher the full population scale variability in medicinal product PKs and molecular target variability, (2) empower forecasting of pharmacovigilance signals within and across populations through knowledge of biomarker variations worldwide, and (3) integration of pharmacovigilance signals across government ministries, civil society organizations, and other stakeholders through, for example, institutional innovation such as centers for panvigilance. We note that panvigilance and pharmacovigilance are complementary, and underscore the added value of panvigilance for global clinical trials. Panvigilance offers a new opportunity for meaningful biomarker application in clinical trials beyond traditional contexts such as personalized medicine. In sum, panvigilance is a systems approach to pharmacovigilance and poised to innovate risk governance in medicinal product development and clinical trials.

Source

Omics-A Journal of Integrative Biology

Volume

23

Issue

3

URI

https://doi.org/10.1089/omi.2019.0020
https://hdl.handle.net/20.500.12713/660

Collections

  • Eczacılık Meslek Bilimleri Bölümü Makale Koleksiyonu [40]
  • Eczacılık Teknolojisi Bölümü Makale Koleksiyonu [8]
  • PubMed İndeksli Yayınlar Koleksiyonu [1162]
  • Scopus İndeksli Yayınlar Koleksiyonu [1924]
  • WoS İndeksli Yayınlar Koleksiyonu [2043]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@İSÜ

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution AuthorThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution Author

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide|| Instruction || Library || İstinye University || OAI-PMH ||

İstinye University, İstanbul, Turkey
If you find any errors in content, please contact:

Creative Commons License
İstinye University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@İSÜ:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.